Liver cirrhosis
Conditions
Interventions
Experimental group:Tetralogy of viable bifidobacterium tablets
Control group:Placebo
Sponsors
Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years old, male or female; 2. All cases refer to the 2015 guidelines for the prevention and treatment of chronic hepatitis B and the unified standard proposed by Anthony, and meet the diagnostic criteria for liver cirrhosis; 3. Signed the informed consent to participate in the research; 4. Suffering from liver cirrhosis, plan to place TIPS in the near future for the treatment of ascites or refractory pleural effusion or the prevention of gastrointestinal bleeding related to portal hypertension.
Exclusion criteria
Exclusion criteria: 1. Patients with liver cirrhosis combined with liver cancer confirmed by CT or MRI, histopathology, or gastric cancer, pancreatic cancer and other malignant tumors confirmed by histopathology; 2. Child Pugh score > 12; 3. Patients who need TIPS for other reasons; 4. Patients with liver cirrhosis combined with systemic lupus erythematosus, Crohn's disease, ulcerative colitis and other inflammatory bowel diseases; patients with liver cirrhosis combined with blood system diseases; 5. Severe heart and lung dysfunction; 6. Has a history of drinking alcohol or using antibiotics or probiotics in the past month; 7. Patients after splenectomy or splenic artery embolization; 8. Patients with a history of gastrointestinal or gastrointestinal surgery; 9. Suffering from neurological diseases, such as Alzheimer's disease, Parkinson's disease, non-hepatic metabolic encephalopathy; 10. Use of antipsychotic drugs, such as antidepressants or sedatives; 11. Patients with a history of overt hepatic encephalopathy; 12. Pregnant or lactating women; 13. Patients who have undergone liver transplantation; 14. The investigator believes that there are other patients who are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Hepatic encephalopathy;Gut microbiota;Metabolomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory index; | — |
Countries
China
Contacts
Public ContactShiming Yang
Xinqiao Hospital, Army Medical University
Outcome results
None listed